|
Market Closed -
Nasdaq
21:00:00 03/09/2026 BST
|
5-day change | 1st Jan Change | ||
| 63.88 USD | +1.22% |
|
+3.17% | +65.32% |
| 09-02 | Teva's immune disorder drug meets main goal in mid-stage trial | RE |
| 08-13 | Zealand Pharma sells rusfertide rights for $100m | FW |
| Market Cap | 28.44B 24.47B 22.97B 21.01B 39.22B 2,689B 39.53B 272B 106B 1,374B 107B 104B 4,426B | P/E 2026 * |
25.9x | P/E 2027 * | 18.1x |
|---|---|---|---|---|---|
| Enterprise Value | 37.55B 32.31B 30.32B 27.74B 51.78B 3,550B 52.19B 359B 140B 1,814B 141B 138B 5,843B | EV / Sales 2026 * |
10.7x | EV / Sales 2027 * | 9.89x |
| Free-Float |
72.41% | Yield 2026 * |
1.59% | Yield 2027 * | 1.67% |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| RPRX | Delayed | |
CBOE
| RPRX | Real-time | |
|
Mexican S.E.
| RPRX N | End-of-day quote | |
|
Deutsche Boerse AG
| RPD | Delayed | |
|
Tradegate
| RPD | Real-time | |
|
Boerse Muenchen
| RPD | Real-time | |
|
Xetra
| RPD | Delayed | |
|
Börse Stuttgart
| RPD | Delayed |
Last Transcript : Royalty Pharma plc
| 1 day | +1.22% | ||
| 1 week | +3.17% | ||
| Current month | +4.02% | ||
| 1 month | +11.74% | ||
| 3 months | +16.21% | ||
| 6 months | +34.54% | ||
| Current year | +65.32% |
| 1 week | 60.39 |  | 63.94 |
| 1 month | 56.53 | | 63.94 |
| Current year | 38.29 | | 63.94 |
| 1 year | 34.08 | | 63.94 |
| 3 years | 24.05 | | 63.94 |
| 5 years | 24.05 | | 63.94 |
| 10 years | 24.05 | | 63.94 |
| Manager | Title | Age | Since |
|---|---|---|---|
Pablo Legorreta
CEO | Chief Executive Officer | 62 | 31/12/1995 |
Terrance Coyne
DFI | Director of Finance/CFO | 44 | 31/12/2009 |
Eric Schneider
CTO | Chief Tech/Sci/R&D Officer | - | 20/09/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
Pablo Legorreta
CHM | Chairman | 62 | 31/03/2020 |
Gregory Norden
BRD | Director/Board Member | 68 | 10/02/2020 |
Bonnie Bassler
BRD | Director/Board Member | 63 | 15/06/2020 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 19/08/26 | Don | Executive/Senior Manager | -16,800 | 0.0038% | ||
| 13/08/26 | Sell | Chief Financial Officer | -11,002 | 0.0025% | ||
| 07/08/26 | Don | Chief Financial Officer | -18,500 | 0.0754% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.22% | +3.17% | +74.25% | +111.03% | 28.44B | |
| -0.04% | -1.40% | +57.16% | +108.15% | 1,034B | |
| +1.17% | +4.76% | +56.42% | +73.50% | 671B | |
| -0.58% | +0.80% | +22.82% | +75.58% | 460B | |
| -0.52% | -1.14% | +28.62% | +37.63% | 353B | |
| -1.17% | +4.90% | +24.90% | +45.79% | 309B | |
| -0.07% | +1.38% | -0.44% | +13.52% | 255B | |
| +0.29% | +1.63% | +56.46% | +73.00% | 240B | |
| -0.54% | +1.56% | -16.75% | -54.21% | 207B | |
| +1.08% | +1.59% | +33.83% | +97.29% | 188B | |
| Average | -0.11% | +1.46% | +33.73% | +58.13% | 374.52B | |
| Weighted average by Cap. | -0.27% | +1.06% | +38.36% | +67.93% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 3.5B 3.01B 2.82B 2.58B 4.82B 331B 4.86B 33.4B 13.01B 169B 13.13B 12.84B 544B | 3.81B 3.28B 3.08B 2.81B 5.25B 360B 5.29B 36.39B 14.17B 184B 14.31B 13.99B 593B |
| Net income | 1.47B 1.26B 1.19B 1.09B 2.03B 139B 2.04B 14.04B 5.47B 71.01B 5.52B 5.4B 229B | 1.79B 1.54B 1.45B 1.33B 2.47B 170B 2.49B 17.14B 6.67B 86.68B 6.74B 6.59B 279B |
| Net Debt | 9.11B 7.84B 7.36B 6.73B 12.56B 861B 12.66B 87.02B 33.89B 440B 34.21B 33.47B 1,417B | 9.22B 7.93B 7.44B 6.81B 12.71B 872B 12.81B 88.06B 34.29B 445B 34.62B 33.87B 1,434B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 03/09/26 | US$63.88 | +1.22% | 2,761,485 |
| 02/09/26 | US$63.11 | +1.27% | 3,143,774 |
| 01/09/26 | US$62.32 | +1.48% | 2,629,306 |
| 31/08/26 | US$61.41 | +0.92% | 3,895,209 |
| 28/08/26 | US$60.85 | -1.73% | 1,701,654 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- RPRX Stock
Select your edition
All financial news and data tailored to specific country editions
